ROBERT POLK: Open Payments
NPI 1982287314 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$873 in 31 payments from 9 companies in 2025. Trend: 2023 $3,125 · 2024 $2,750 · 2025 $873
Food & beverage: $873
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $196 |
| Teva Pharmaceuticals USA, Inc. | 6 | $162 |
| Neurocrine BioSciences, Inc. | 4 | $106 |
| ABBVIE INC. | 4 | $93 |
| Axsome Therapeutics, Inc. | 2 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Janssen Pharmaceuticals, Inc | 2 | $70 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Alkermes, Inc. | 1 | $20 |
Products named: CAPLYTA, AUSTEDO XR, INGREZZA, VRAYLAR, Auvelity, SPRAVATO, COBENFY, REXULTI.
Industry payments across TX — which companies pay providers there.
